New Boron Chemistry Revolutionizes Protein Synthesis for Medicine and Science
Many crucial proteins for modern medicine and science exhibit poor solubility, leading to clumping and loss of function beyond certain concentrations. This characteristic significantly hinders their synthetic production in laboratories, as existing chemical coupling methods for protein fragments necessitate high concentrations.
Researchers at ETH Zurich, led by Professor Jeffrey Bode, have developed a groundbreaking new method that enables the coupling of even poorly soluble protein segments into functional proteins. This innovative method utilizes the unique properties of a chemical compound containing boron, promising to overcome long-standing obstacles in synthetic biology.
Unprecedented Reaction Speed
The key distinction of the ETH method is its significantly faster coupling reaction speed, approximately 1,000 times quicker than conventional approaches. This remarkable increase in speed allows the reaction to occur at 1,000 times lower concentrations. This directly addresses the limitations imposed by slow carbon chemistry, which traditionally requires high reactant concentrations in laboratory settings.
Boron: The Key to Chemical Acceleration
The acceleration was achieved by incorporating boron atoms into carbon-based molecules – elements not naturally found in biological molecules. Boron, a metalloid, displays distinct properties when bonded with metals or nonmetals, forming materials with unusual reaction characteristics.
Boron-based coupling reactions have previously been recognized with the Nobel Prize in Chemistry for their pivotal role in synthesizing natural substances.
According to Professor Bode, "extending into boron-based reagents allows for rapid execution of challenging reactions involving large biological molecules, overcoming inherent limitations of purely carbon-based systems."
From Early Promise to Robust Solution
Initial research in 2012 by Bode's team successfully demonstrated the rapid and reliable joining of protein fragments using a carbon compound combining boron and fluorine. However, this early compound lacked the necessary stability in strong acids, rendering it unsuitable for automated synthesis processes.
After four years of dedicated research, a significant breakthrough occurred: the discovery of a protective chemical packaging that effectively shields the sensitive boron group. This crucial protection now allows the compound to withstand the acidic conditions typically encountered during automated protein production, making the method viable for industrial applications.
Broad Horizons for Medicine and Science
This novel ETH method significantly facilitates the production of new peptide and protein medications. This includes medically important membrane proteins, which are notoriously prone to clumping, using standard laboratory techniques.
The method also enables the targeted introduction of unnatural amino acids with specific properties into poorly soluble proteins. This capability is especially significant for applications such as linking proteins to active substances, a technique crucial for antibody-drug conjugates used in cancer therapies to specifically target cancerous tissue.
Advancing Clinical Integration
The clinical integration of this method is still being explored. Professor Bode cofounded Bright Peak Therapeutics in 2020, an ETH spin-off dedicated to developing immunotherapies for cancer using technologies stemming from his research group. An initial therapeutic agent from Bright Peak Therapeutics is currently in clinical trials, and the new boron-based method holds immense potential to further expand the spin-off's product pipeline and impact future medical treatments.